Propranolol: What is BLOCKing its clinical investigation in breast cancer?

Anne H. Blaes, Evidio Domingo-Musibay, Kevin Kalinsky

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803.

Original languageEnglish (US)
Pages (from-to)1781-1783
Number of pages3
JournalClinical Cancer Research
Issue number8
StatePublished - Apr 15 2020

Bibliographical note

Publisher Copyright:
© 2020 American Association for Cancer Research.


  • Biomarkers
  • Breast Neoplasms
  • Cell Line, Tumor
  • Cell Proliferation
  • Epithelial-Mesenchymal Transition
  • Humans
  • Propranolol
  • Tumor Microenvironment

PubMed: MeSH publication types

  • Comment
  • Research Support, Non-U.S. Gov't
  • Journal Article


Dive into the research topics of 'Propranolol: What is BLOCKing its clinical investigation in breast cancer?'. Together they form a unique fingerprint.

Cite this